

Danilo Marimpietri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/650791/publications.pdf>

Version: 2024-02-01

61
papers

2,773
citations

147726

31
h-index

175177

52
g-index

65
all docs

65
docs citations

65
times ranked

3946
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | Mini-Tablets: A Valid Strategy to Combine Efficacy and Safety in Pediatrics. <i>Pharmaceutics</i> , 2022, 15, 108. | 1.7 | 17 |
| 2 | Pyrazole-Based Water-Soluble Dendrimer Nanoparticles as a Potential New Agent against Staphylococci. <i>Biomedicines</i> , 2022, 10, 17. | 1.4 | 12 |
| 3 | Potent and Broad-Spectrum Bactericidal Activity of a Nanotechnologically Manipulated Novel Pyrazole. <i>Biomedicines</i> , 2022, 10, 907. | 1.4 | 5 |
| 4 | Enhanced Antibacterial Activity of a Cationic Macromolecule by Its Complexation with a Weakly Active Pyrazole Derivative. <i>Biomedicines</i> , 2022, 10, 1607. | 1.4 | 3 |
| 5 | The Role of Extracellular Vesicles in the Progression of Human Neuroblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3964. | 1.8 | 11 |
| 6 | Increased Water-Solubility and Maintained Antioxidant Power of Resveratrol by Its Encapsulation in Vitamin E TPGS Micelles: A Potential Nutritional Supplement for Chronic Liver Disease. <i>Pharmaceutics</i> , 2021, 13, 1128. | 2.0 | 24 |
| 7 | The Depolarization-Evoked, Ca ²⁺ -Dependent Release of Exosomes From Mouse Cortical Nerve Endings: New Insights Into Synaptic Transmission. <i>Frontiers in Pharmacology</i> , 2021, 12, 670158. | 1.6 | 15 |
| 8 | Bactericidal Activity of Non-Cytotoxic Cationic Nanoparticles against Clinically and Environmentally Relevant Pseudomonas spp. Isolates. <i>Pharmaceutics</i> , 2021, 13, 1411. | 2.0 | 16 |
| 9 | Identification of Biochemical and Molecular Markers of Early Aging in Childhood Cancer Survivors. <i>Cancers</i> , 2021, 13, 5214. | 1.7 | 5 |
| 10 | Efficacy of Ursolic Acid-Enriched Water-Soluble and Not Cytotoxic Nanoparticles against Enterococci. <i>Pharmaceutics</i> , 2021, 13, 1976. | 2.0 | 8 |
| 11 | Human Amnion Epithelial Cells Impair T Cell Proliferation: The Role of HLA-G and HLA-E Molecules. <i>Cells</i> , 2020, 9, 2123. | 1.8 | 19 |
| 12 | Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study. <i>Cancers</i> , 2019, 11, 1476. | 1.7 | 43 |
| 13 | Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells. <i>Oncolmmunology</i> , 2019, 8, e1574198. | 2.1 | 29 |
| 14 | CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies. <i>Cells</i> , 2019, 8, 1527. | 1.8 | 56 |
| 15 | Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD ⁺ . <i>Oncolmmunology</i> , 2018, 7, e1458809. | 2.1 | 59 |
| 16 | <i>CHL1</i> gene acts as a tumor suppressor in human neuroblastoma. <i>Oncotarget</i> , 2018, 9, 25903-25921. | 0.8 | 24 |
| 17 | Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes. <i>Molecular Cancer</i> , 2017, 16, 159. | 7.9 | 55 |
| 18 | Exosomes from human mesenchymal stem cells conduct aerobic metabolism in term and preterm newborn infants. <i>FASEB Journal</i> , 2016, 30, 1416-1424. | 0.2 | 63 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | NAD ⁺ -Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model. <i>Cells</i> , 2015, 4, 520-537. | 1.8 | 99 |
| 20 | The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma. <i>Leukemia</i> , 2015, 29, 958-967. | 3.3 | 31 |
| 21 | Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. <i>Annals of the New York Academy of Sciences</i> , 2015, 1335, 10-22. | 1.8 | 47 |
| 22 | Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells. <i>Blood</i> , 2015, 126, 1849-1849. | 0.6 | 16 |
| 23 | Abstract 1149: Consistency between genomic and proteomic profiles reveals novel molecular mechanisms of fasting antitumor activity. , 2015, , . | | 0 |
| 24 | ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. <i>Cell Death and Disease</i> , 2014, 5, e1135-e1135. | 2.7 | 102 |
| 25 | Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia. <i>Oncotarget</i> , 2014, 5, 10368-10381. | 0.8 | 18 |
| 26 | Abstract 3374: Fasting chemosensitizes tumor cells by affecting their metabolism. , 2014, , . | | 1 |
| 27 | Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma. <i>Journal of Controlled Release</i> , 2013, 170, 445-451. | 4.8 | 41 |
| 28 | Proteome Profiling of Neuroblastoma-Derived Exosomes Reveal the Expression of Proteins Potentially Involved in Tumor Progression. <i>PLoS ONE</i> , 2013, 8, e75054. | 1.1 | 122 |
| 29 | Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. <i>Cell Research</i> , 2011, 21, 1470-1486. | 5.7 | 66 |
| 30 | Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma. <i>Cancer Research</i> , 2010, 70, 9816-9826. | 0.4 | 65 |
| 31 | Chapter 12 Liposome-Mediated Therapy of Neuroblastoma. <i>Methods in Enzymology</i> , 2009, 465, 225-249. | 0.4 | 13 |
| 32 | The Combined Therapeutic Effects of Bortezomib and Fenretinide on Neuroblastoma Cells Involve Endoplasmic Reticulum Stress Response. <i>Clinical Cancer Research</i> , 2009, 15, 1199-1209. | 3.2 | 39 |
| 33 | Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides. <i>Journal of Controlled Release</i> , 2009, 138, 122-127. | 4.8 | 13 |
| 34 | Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model. <i>Current Drug Targets</i> , 2009, 10, 1021-1027. | 1.0 | 14 |
| 35 | Abstract A130: Effects of a novel liposomal formulation of fenretinide on human neuroblastoma cell growth, apoptosis and angiogenesis. , 2009, , . | | 0 |
| 36 | Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin. <i>Clinical Cancer Research</i> , 2008, 14, 7320-7329. | 3.2 | 82 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Drug Delivery Systems: Application of Liposomal Anti-Tumor Agents to Neuroectodermal Cancer Treatment. <i>Tumori</i> , 2008, 94, 246-253. | 0.6 | 19 |
| 38 | Combined Therapeutic Effects of Vinblastine and Rapamycin on Human Neuroblastoma Growth, Apoptosis, and Angiogenesis. <i>Clinical Cancer Research</i> , 2007, 13, 3977-3988. | 3.2 | 77 |
| 39 | Ligand-Targeted Liposomal Therapies of Neuroblastoma. <i>Current Medicinal Chemistry</i> , 2007, 14, 3070-3078. | 1.2 | 28 |
| 40 | Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line. <i>Proteomics</i> , 2006, 6, 4420-4431. | 1.3 | 20 |
| 41 | Targeting Liposomal Chemotherapy via Both Tumor Cell-Specific and Tumor Vasculature-Specific Ligands Potentiates Therapeutic Efficacy. <i>Cancer Research</i> , 2006, 66, 10073-10082. | 0.4 | 215 |
| 42 | Effect of Bortezomib on Human Neuroblastoma Cell Growth, Apoptosis, and Angiogenesis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1142-1157. | 3.0 | 125 |
| 43 | Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. <i>Oncogene</i> , 2005, 24, 6785-6795. | 2.6 | 63 |
| 44 | Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities. <i>Cancer Letters</i> , 2005, 228, 181-186. | 3.2 | 29 |
| 45 | Immune Cell-Mediated Antitumor Activities of GD2-Targeted Liposomal c-myb Antisense Oligonucleotides Containing CpG Motifs. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1171-1180. | 3.0 | 61 |
| 46 | Targeted Delivery of Oncogene-Selective Antisense Oligonucleotides in Neuroectodermal Tumors: Therapeutic Implications. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 90-103. | 1.8 | 13 |
| 47 | Angiogenesis in Neuroblastoma. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 133-142. | 1.8 | 62 |
| 48 | Proteomic analysis of an orthotopic neuroblastoma xenograft animal model*1. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 808, 279-286. | 1.2 | 14 |
| 49 | In vitro and in vivo antitumor activity of liposomal fenretinide targeted to human neuroblastoma. <i>International Journal of Cancer</i> , 2003, 104, 559-567. | 2.3 | 41 |
| 50 | Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 151-155. | 3.2 | 36 |
| 51 | Development of Fab'2 fragments of anti-GD2 immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 199-204. | 3.2 | 41 |
| 52 | Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. <i>Cancer Letters</i> , 2003, 197, 205-209. | 3.2 | 37 |
| 53 | Fenretinide as an anti-angiogenic agent in neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 181-184. | 3.2 | 20 |
| 54 | Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. <i>Cancer Letters</i> , 2003, 197, 231-235. | 3.2 | 47 |

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. <i>Cancer Research</i> , 2003, 63, 86-92. | 0.4 | 122 |
| 56 | Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. <i>Clinical Cancer Research</i> , 2003, 9, 4595-605. | 3.2 | 53 |
| 57 | Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. <i>Cancer Research</i> , 2003, 63, 7400-9. | 0.4 | 242 |
| 58 | Inhibition of neuroblastoma-induced angiogenesis by fenretinide. <i>International Journal of Cancer</i> , 2001, 94, 314-321. | 2.3 | 63 |
| 59 | Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells. <i>Cell Proliferation</i> , 2000, 33, 139-146. | 2.4 | 66 |
| 60 | Tissue transglutaminase is a caspase substrate during apoptosis. Cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation. <i>Cell Death and Differentiation</i> , 1999, 6, 992-1001. | 5.0 | 39 |
| 61 | Biochemical characterization and membrane expression of an antigen shared by activated and neoplastic cells of neuroectodermal origin. <i>Journal of Neuroimmunology</i> , 1995, 57, 17-26. | 1.1 | 4 |